U.S. License Holder:
Date of License:
aBLA submitted to FDA November-2022
ABP 654 (ustekinumab) is not FDA-approved. An aBLA has been submitted to the FDA.
U.S. Patent LitigationsPACER
U.S. Patent Nos.
6,902,734 (Anti-IL-12 Antibodies and Compositions Thereof) 10,961,307 (Methods of Treating Moderately to Severely Active Ulcerative Colitis by Administering an Anti-IL12/IL23 Antibody)
Janssen Biotech, Inc.